# Treating Tobacco Use Disorders: Evidence-Based Guidelines for Practitioners

Lori Karan, MD, DFASAM Michael Weaver, MD, DFASAM

April 1, 2022



#### **Disclosure Information**

- \* Presenter 1: Lori Karan, MD, DFASAM
  - No Disclosures
- Presenter 2: Michael Weaver, MD, DFASAM
  - No Disclosures



## **Learning Objectives**

- Identify different tobacco products, including combustible cigarettes, smokeless products, and electronic nicotine delivery systems.
- Compare and contrast evidence-based behavioral and pharmacotherapy options for treatment of tobacco use disorder, including nicotine replacement products, varenicline, and bupropion.
- Discuss the management of patients with co-occurring psychiatric disorders, including the impact of smoking and stopping smoking.
- \* Discuss the management of patients with co-occurring substance use disorders



#### Case #1 SW





- Hospitalized for pneumonia complicating COPD pO2=65% when admitted to hospital 6mo ago
- Now, pO2 on room air is normal (98%), even as he continues to smoke
- **\*SW** lives independently
- #He walks slowly due to back and knee ailments



#### Case #1 SW (cont 2)



- Family members and physicians repeatedly urge SW to quit smoking
- SW gets anxious and responds by changing the subject and avoiding the issue
- \* SW chain smokes; onset 16y/o, max 4ppd, now 1.5 ppd
- SW smokes within seconds of awakening
- SW gets up and leaves conversations to smoke, even when doing so is not socially appropriate



#### Case #1 SW (cont 3)



**\*SW** did not smoke for a few days when he was ill.

\*SW has tried smoking cessation books, classes, & groups, as well as nicotine gum and the patch



#### Case #1 SW



How do you assess the severity of SW's nicotine withdrawal and nicotine addiction?

What is the most appropriate level of care to treat SW?



## **Smoking Tobacco**

- Cigarettes, cigars, pipes
- Many different harmful compounds
- Stimulant & relaxes
- **\***Acute effects
  - **\*** Vasoconstriction
- Very short-acting, so highfrequency use
  - Very reinforcing









#### **Smokeless tobacco**







- **\***Products
  - Chewing tobacco
  - # "snuff"
  - **\*** Snus
- Used by 3.3% of U.S. population
  - Prevalence of use has not decreased like tobacco cigarette smoking
- Exposure to more nicotine & carcinogens than cigarettes

## **Electronic cigarettes**

- Neither designed nor marketed for smoking cessation
- Intentionally attractive to youth with flavorings (bubblegum, etc.)
- \*Introduced in U.S. in 2006, only became regulated in U.S. in 2018
- Less harmful than tobacco, but more dangerous than air



CALIFORNIA PROPOSITION 65 Warning: This product contains nicotine, a chemical known to the state of Calif



## Juul pods





- # 1 pod = 20 tobacco cigarettes (I pack)
- Used discreetly in places where smoking is forbidden
  - School bathrooms
  - \* Looks like a flash drive
  - Charges in USB port
- \*1/5 of middle & high school students have seen Juul used in school



## Psychiatric disorders & Nicotine

- \*Tobacco use is more prevalent & intense among psychiatric patients
- Up to 88% of patients with schizophrenia smoke
- #40% of patients with ADHD smoke
- \*36% of all psychiatric patients smoke
- More difficulty quitting

- #Higher rates of depression & anxiety among smokers
  - \*59% of smokers have a lifetime history of depression
- Higher suicide rates
  - \*2x higher risk in smokers





#### DSM-5 Tobacco Use Disorder > 2 Criteria within 12 mo

- 1. Taken in larger amts or over a longer period of time than intended
- 2. Persistent desire or unsuccessful efforts to cut down or control use
- 3. A great deal of time is spent in activities necessary to obtain or use
- 4. Craving, or a strong desire or urge to use tobacco
- 5. Recurrent use → failure to fulfill major role obligations (work, school, home)
- 6. Continued use despite social or interpersonal problems
- 7. Important social, occupational, or recreational activities reduced
- 8. Recurrent use when physically hazardous (i.e., smoking in bed)
- 9. Tobacco use is continued despite knowledge of physical or psychological problem exacerbated by tobacco



#### DSM-5 Tobacco Use Disorder ≥ 2 Criteria within 12 mo

- 10. Tolerance, as defined by either:
  - a. A need for markedly 1 tobacco to achieve the desired effect

- 11. Withdrawal, as defined by either:
  - a. Characteristic withdrawal syndrome
  - b. Tobacco (or nicotine) is taken to relieve withdrawal sx



#### **Assessing Severity: DSM-5 Problems**

#### General DSM issues:

Measures are context-specific

No threshold to determine if a specific criteria is met

#### Nicotine vs other drugs:

1. Nicotine does not cause gross intoxication

not socially acceptable ≠ behavioral disruption caused by intoxication

Judgment is not worsened by nicotine use

Less interference with role obligations & interpersonal relations

2. Dose escalation and tolerance are less important



#### Fagerstrom Test For Nicotine Dependence

How soon after you wake up do you smoke your first cigarette? <5 min $\square$ 3 6-30 min $\square$ 2 31-60 min $\square$ 1 >60 min $\square$ 0	0-3
Do you find it difficult to refrain from smoking in places where it is forbidden i.e., in church, at the library, in cinemas, etc? Yes $\Box$ 1 No $\Box$ 0	0-1
Which cigarette would you hate most to give up? 1 <sup>st</sup> one of the morning $\Box$ 1 any other $\Box$ 0	0-1
How many cigarettes do you smoke? >31  3 21-30  2 11-20  1 <10  0	0-3
Do you smoke more frequently during the first hours after awakening for the day? Yes $\ \square$ 1 No $\ \square$ 0	0-1
Do you smoke when you are so ill that you are in bed most of the day? (I you never get sick, give the most likely response) Yes $\Box$ 1 No $\Box$ 0	0-1
TOTAL (10 points possible - most severe)	

## Why is nicotine so addicting?

- #Early onset
  - Often 1<sup>st</sup> drug used (including as a fetus)
- \*Rapid onset of action
- Fine-tunes behavior (both stimulates + relaxes)
- \*Rapid onset of action (cigarette enables 'freebase')
- Can self-adjust dose
- Numerous doses each day (1 pack = 200 puffs)
- **#**Use linked with environmental and internal cues



## **Nicotine Pharmacotherapy**

- Replacement
  - nicotine patches
  - nicotine gum
  - nicotine lozenges
  - micotine inhaler (puffer)
  - nicotine nasal spray

- \*\*Antidepressants
  - Bupropion (Zyban)
- \*Partial agonists
  - Varenicline (Chantix)





#### **Nicotine Patch**

- Highest success rate of available nicotine replacement pharmacotherapies
- \*Nicoderm, Nicotrol, Habitrol, Prostep
- \*Most come in 3 strengths: 21, 14, & 7mg
- \*\*Start with 21mg patch for 6 wks, taper to 14 mg for 2-4 wks, finally 7 mg for 2-4 weeks
- #Use new patch in different spot on upper trunk every 24 hrs



## Nicotine Gum & Lozenges

- **\***2 or 4mg
- #Gum: "chew and park"-- don't chew like regular chewing gum
- \*Lozenge: let dissolve
- \*Requires basic pH for mucosal absorption (avoid coffee, etc.)
- Use as needed: i.e., 1 piece for 30 minutes every 1 to 2 hours to prevent nicotine withdrawal








## Nicotine Inhaler (Puffer)

Assists with handling (hand-mouth ritual)
Do not deeply inhale
Nicotine is absorbed in mucosa & back of throat
Caution: bronchospasm













## Nicotine Nasal Spray

Prime pump (before first use)
1 spray in each nostril =2 sprays- 1mg nicotine

Nasal irritation
Can trigger cravings in patients with hx intranasal drug use







## Varenicline (Chantix)



- Nicotine partial agonist
- Start pills 10 days before quit date
  - Increase dose
  - **\***Take for 12-24 weeks
- Includes behavioral program
  - #GetQuit.com



## **Bupropion (Zyban)**

- \*Bupropion 150mg sustained release pills
- \*\*Works on dopamine & norepinephrine receptors in the brain to decrease withdrawal
- May cause insomnia, anxiety, or seizures
- Prescription includes behavioral program

- Start pills 10-14 days before "quit date"
- Take daily for 3 days, then twice a day
- **\***Continue pills for 8 12 weeks





#### Efficacy of tobacco cessation products

There have been many studies and several meta-analyses of all products

Varenicline

- Higher rate of continuous tobacco abstinence
- Compared to bupropion & nicotine patch

Nicotine replacement therapy


- Quit rates are similar with different products
- Patch, gum, lozenge
- Doubles chance of successful quitting

**Bupropion** 

Quit rates are comparable to nicotine patch



## Plasma nicotine levels – contrast between cigarettes and NRT





#### **Combination therapy**

- Combinations are more effective than a single product at a time
- Patch + gum/lozenge

- ★ Varenicline + NRT
  - **\***Superior to either alone
  - Can start both together
    - Patch faster for withdrawal symptoms
- Varenicline + bupropion
  - Do not interact
  - Good for heavy smokers



#### Case #1 SW

- Severe Nicotine Addiction
  - Death imminent if smoking continues
  - Physically Dependent, Prior Tries & Unable to Quit
- **\***Education & Intervention
- \*Refer to Residential Treatment
  - \*Intensive Pharmacotherapeutic Intervention
  - Intensive Behavioral & Addictions Rx





#### Case #2: TH



**\*50** y/o Addiction Counselor - Residential Rx Center

\*Rx Center to begin treating tobacco addiction along with all other addictions

\* Staff cannot smell of smoke, nor smoke at work



#### Case #2: TH (cont 2)



- "Recovery" alcohol & pain meds x 23 yrs
- \* Always knew tobacco was not part of his disease
- # Feels extra rapport when takes smoking breaks with pts
- \*Advised pts, who wanted to stop smoking, to wait > 1 yr "it is too hard to quit more than one thing at a time."



#### Case #2: TH (cont 3)



- Frequent bronchitis
- **\*MD** told to stop before permanent lung damage
- **\*40** lbs overweight, fears wt gain if quits cigs
- \*Angry that workplace is forcing him to quit smoking



#### Addiction Professionals: Issues

- **\*Staff may have belief system about Nicotine Addiction** 
  - **\***"You can only deal with one addiction at a time."
  - "You should wait a year before you attempt to stop."
  - "Tobacco use disorders are less harmful than the immediate consequences of alcohol or illicit drug use."



#### Addiction Professionals: Issues

- **\***Staff who are still smoking themselves:
  - \*May be reticent to diagnose and treat tobacco addiction
  - \*May be tempted to use smoking time as "milieu management"
  - \*May "feel sorry" for the patients and sabotage the patients' treatment




#### Addiction Professionals: Issues

- Leadership must recognize that TUD can no longer be ignored during prevention, diagnosis, and treatment of other addictions & mental illness
- Staff need to be trained in diagnosis and treatment of TUD
- \*All facility staff, including clinical and non-clinical support staff should not smell of tobacco
- All staff who want to quit should have access to pharmacotherapy& support for cessation




#### INTEGRATING TUD TREATMENT WITH OTHER SUD TREATMENT



#### **SUMMARY OF RECOMMENDATIONS**

- 1. Screen all patients for tobacco use disorder
- 2. Offer evidence-based treatment to all patients with tobacco use disorder
- 3. Use motivational and harm reduction strategies for patients ambivalent about quitting
- 4. Implement organizational policies to support treatment of tobacco use disorder

# Integrating Tobacco Use Disorder Interventions in Addiction Treatment







#### **Takeaway Points**

- \*Ask all patients about smoking, and also about electronic nicotine delivery systems and smokeless tobacco products
- \*Advise all patients to stop use of all nicotine/tobacco products
- Medications are very effective to help patients successfully quit
- Combinations of medications are better than monotherapy
- Stopping nicotine use improves recovery from other substances



#### References

- ASAM Quality Improvement Council. Integrating Tobacco Use Disorder Interventions in Addiction Treatment: A Guide for Addiction Treatment Clinicians and Programs, 2022
- \* Breland, A.B., Almond, L., Kienzle, J., et al: Targeting Tobacco in a Community-Based Addiction Recovery Cohort: Results from a Computerized, Brief, Randomized Intervention Trial. Contemporary Clinical Trials, 2014.
- Rigotti, N.A., Kruse, G.R., Livingstone-Banks, J., Hartmann-Boyce, J. Treatment of Tobacco Smoking: A Review. JAMA 2022; 327(6):566-577.

- Weaver, M.F., Breland, A.B., Spindle, T., Eissenberg, T.: Electronic cigarettes: a review of safety and clinical issues. Journal of Addiction Medicine, 8(4): 234-240, 2014.
- West R, et al.: Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES. Addiction 2018;113(8):1507-1516.







Annual2022

## **Questions?**



